Jaw-Dropping Explosions on The Sun Captured in First NASA PUNCH Images
A NASA mission to observe the activity of the solar wind has returned its first images of giant coronal mass ejections (CMEs) billowing out from the Sun.
Images from the Polarimeter to Unify the Corona and Heliosphere (PUNCH) were presented at the 246th meeting of the American Astronomical Society, showing these giant events on an unprecedented scale.
"I promise you you have never seen anything quite like this," heliophysicist and PUNCH principal investigator Craig DeForest of the Southwest Research Institute said in his presentation.
CMEs are huge expulsions of billions of tons of solar plasma and magnetic fields that are blasted out from the Sun, a massive release of energy and solar particles that occurs when the Sun's magnetic field lines tangle, snap, and reconnect. They often, but don't always, occur with solar flares.
A halo CME is what we call it when the CME blasts right in the direction of Earth. From our perspective, the expanding ejecta looks to surround the Sun like a halo, before barreling through the Solar System at tremendous speed.
"That halo CME is something you have never seen before. I'd like to call your attention to the white circle near the center of the field of view here. That circle represents the LASCO field of view; that is the largest coronagraph currently used to forecast space weather.
"You've seen halo CME movies before, if you've paid attention to the science press. But you have never seen one 30 to 40 degrees from the Sun … you're seeing something that is literally washing across the entire sky of the inner Solar System as it comes toward the Earth."
In this case, they were able to track a CME as it blasted through the Solar System at 4 million miles an hour until about two hours before it collided with Earth's magnetic field. These events often produce the aurora that light up Earth's polar skies, but can also interrupt communications and damage satellites, so scientists are keen to develop better space weather tracking and prediction tools.
PUNCH is just beginning its planned two-year mission to record solar events in 3D, in an attempt to better understand space weather. The four probes aren't quite yet in their final positions, but the team here on Earth is testing the instruments and taking observations.
"These are preliminary data. They look good now, but they are going to look fabulous once we are done with calibration later this summer," DeForest said. "This is the first of many, I'm sure, and the best is still to come."
SpaceX Starship Explodes in Towering Fireball
Astronomers Uncover a Massive Shaft of Missing Matter
Our Galaxy's Monster Black Hole Is Spinning Almost as Fast as Physics Allows
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Strange signals detected from Antarctic ice seem to defy laws of physics. Scientists are searching for an answer
Sign up for CNN's Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more. Scientists are trying to solve a decade-long mystery by determining the identity of anomalous signals detected from below ice in Antarctica. The strange radio waves emerged during a search for another unusual phenomenon: high-energy cosmic particles known as neutrinos. Arriving at Earth from the far reaches of the cosmos, neutrinos are often called 'ghostly' because they are extremely volatile, or vaporous, and can go through any kind of matter without changing. Over the past decade, researchers have conducted multiple experiments using vast expanses of water and ice that are designed to search for neutrinos, which could shed light on mysterious cosmic rays, the most highly energetic particles in the universe. One of these projects was NASA's Antarctic Impulsive Transient Antenna, or ANITA, experiment, which flew balloons carrying instruments above Antarctica between 2006 and 2016. It was during this hunt that ANITA picked up anomalous radio waves that didn't seem to be neutrinos. The signals came from below the horizon, suggesting they had passed through thousands of miles of rock before reaching the detector. But the radio waves should have been absorbed by the rock. The ANITA team believed these anomalous signals could not be explained by the current understanding of particle physics. Follow-up observations and analyses with other instruments, including one recently conducted by the Pierre Auger Observatory in Argentina, have not been able to find the same signals. The results of the Pierre Auger Collaboration were published in the journal Physical Review Letters in March. The origin of the anomalous signals remains unclear, said study coauthor Stephanie Wissel, associate professor of physics, astronomy and astrophysics at the Pennsylvania State University. 'Our new study indicates that such (signals) have not been seen by an experiment … like the Pierre Auger Observatory,' Wissel said. 'So, it does not indicate that there is new physics, but rather more information to add to the story.' Larger, more sensitive detectors may be able to solve the mystery, or ultimately prove whether the anomalous signals were a fluke, while continuing the search for enigmatic neutrinos and their sources, scientists say. Detecting neutrinos on Earth allows researchers to trace them back to their sources, which scientists believe are primarily cosmic rays that strike our planet's atmosphere. The most highly energetic particles in the universe, cosmic rays are made up mostly of protons or atomic nuclei, and they are unleashed across the universe because whatever produces them is such a powerful particle accelerator that it dwarfs the capabilities of the Large Hadron Collider. Neutrinos could help astronomers better understand cosmic rays and what launches them across the cosmos. But neutrinos are difficult to find because they have almost no mass and can pass through the most extreme environments, like stars and entire galaxies, unchanged. They do, however, interact with water and ice. ANITA was designed to search for the highest energy neutrinos in the universe, at higher energies than have yet been detected, said Justin Vandenbroucke, an associate professor of physics at the University of Wisconsin, Madison. The experiment's radio antennae search for a short pulse of radio waves produced when a neutrino collides with an atom in the Antarctic ice, leading to a shower of lower-energy particles, he said. During its flights, ANITA found high-energy fountains of particles coming from the ice, a kind of upside-down shower of cosmic rays. The detector is also sensitive to ultrahigh energy cosmic rays that rain down on Earth and create a radio burst that acts like a flashlight beam of radio waves. When ANITA watches a cosmic ray, the flashlight beam is really a burst of radio waves one-billionth of a second long that can be mapped like a wave to show how it reflects off the ice. Twice in their data from ANITA flights, the experiment's original team spotted signals coming up through the ice at a much sharper angle than ever predicted by any models, making it impossible to trace the signals to their original sources. 'The radio waves that we detected nearly a decade ago were at really steep angles, like 30 degrees below the surface of the ice,' Wissel said. Neutrinos can travel through a lot of matter, but not all the way through the Earth, Vandenbroucke said. 'They are expected to arrive from slightly below the horizon, where there is not much Earth for them to be absorbed,' he wrote in an email. 'The ANITA anomalous events are intriguing because they appear to come from well below the horizon, so the neutrinos would have to travel through much of the Earth. This is not possible according to the Standard Model of particle physics.' The Pierre Auger Collaboration, which includes hundreds of scientists around the world, analyzed more than a decade's worth of data to try to understand the anomalous signals detected by ANITA. The team also used their observatory to try to find the same signals. The Auger Observatory is a hybrid detector that uses two methods to find and study cosmic rays. One method relies on finding high-energy particles as they interact with water in tanks on Earth's surface, and the other tracks potential interactions with ultraviolet light high in our planet's atmosphere. 'The Auger Observatory uses a very different technique to observe ultrahigh energy cosmic ray air showers, using the secondary glow of charged particles as they traverse the atmosphere to determine the direction of the cosmic ray that initiated it,' said Peter Gorham, a professor of physics at the University of Hawaii at Mānoa. 'By using computer simulations of what such a shower of particles would look like if it had behaved like the ANITA anomalous events, they are able to generate a kind of template for similar events and then search their data to see if anything like that appears.' Gorham, who was not involved with the new research, designed the ANITA experiment and has conducted other research to understand more about the anomalous signals. While the Auger Observatory was designed to measure downward-going particle showers produced in the atmosphere by ultrahigh-energy cosmic rays, the team redesigned their data analysis to search for upward-going air showers, Vandenbroucke said. Vandenbroucke did not work on the new study, but he peer-reviewed it prior to publication. 'Auger has an enormous collecting area for such events, larger than ANITA,' he said. 'If the ANITA anomalous events are produced by any particle traveling through the Earth and then producing upward-going showers, then Auger should have detected many of them, and it did not.' A separate follow-up study using the IceCube Experiment, which has sensors embedded deep in the Antarctic ice, also searched for the anomalous signals. 'Because IceCube is very sensitive, if the ANITA anomalous events were neutrinos then we would have detected them,' wrote Vandenbroucke, who served as colead of the IceCube Neutrino Sources working group between 2019 and 2022. 'It's an interesting problem because we still don't actually have an explanation for what those anomalies are, but what we do know is that they're most likely not representing neutrinos,' Wissel said. Oddly enough, a different kind of neutrino, called a tau neutrino, is one hypothesis that some scientists have put forth as the cause of the anomalous signals. Tau neutrinos can regenerate. When they decay at high energies, they produce another tau neutrino, as well as a particle called a tau lepton — similar to an electron, but much heavier. But what makes the tau neutrino scenario very unlikely is the steepness of the angle connected to the signal, Wissel said. 'You expect all these tau neutrinos to be very, very close to the horizon, like maybe one to five degrees below the horizon,' Wissel said. 'These are 30 degrees below the horizon. There's just too much material. They really would actually lose quite a bit of energy and not be detectable.' At the end of the day, Gorham and the other scientists have no idea what the origin of the anomalous ANITA events are. So far, no interpretations match up with the signals, which is what keeps drawing scientists back to try to solve the mystery. The answer may be in sight, however. Wissel is also working on a new detector, the Payload for Ultra-High Energy Observations or PUEO, that will fly over Antarctica for a month beginning in December. Larger and 10 times more sensitive than ANITA, PUEO could reveal more information on what is causing the anomalous signals detected by ANITA, Wissel said. 'Right now, it's one of these long-standing mysteries,' Wissel said. 'I'm excited that when we fly PUEO, we'll have better sensitivity. In principle, we should be able to better understand these anomalies which will go a long way to understanding our backgrounds and ultimately detecting neutrinos in the future.' Gorham said that PUEO, an acronym that references the Hawaiian owl, should have the sensitivity to capture many anomalous signals and help scientists find an answer. 'Sometimes you just have to go back to the drawing board and really figure out what these things are,' Wissel said. 'The most likely scenario is that it's some mundane physics that can be explained, but we're sort of knocking on all the doors to try to figure out what those are.'
Yahoo
41 minutes ago
- Yahoo
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL. 'The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of 2025,' said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. 'The preclinical data being presented at ADA include the robust weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist underscoring ACCG-2671's potential as a future small molecule backbone treatment for obesity. In addition, we will present data demonstrating the neuroprotective effects of GLP-1 receptor agonism in preclinical models of Parkinson's disease, reinforcing the broad role of the GLP-1 receptor across different diseases.' Presentation Details: Title: Novel Oral Small Molecule ACCG-2671: A Dual Amylin and Calcitonin Receptor Agonist Development Candidate for Obesity TherapyPoster #: 2184-LBSession: Late Breaking Poster SessionDate: Sunday, June 22Time: 12:30 p.m. – 1:30 p.m. CT Summary: ACCG-2671 demonstrated high binding affinity and balanced potency in human calcitonin receptor (CTR) and amylin receptor (AMY3R) functional assays. In diet-induced obese rats, oral administration of ACCG-2671 resulted in significant, dose-dependent body weight reductions. Combination therapy with semaglutide (both as add-on and concurrent treatment) resulted in superior weight loss compared to monotherapy. Title: Oral Small Molecule GLP-1 Receptor Agonist Demonstrates Beneficial Effects in Parkinson's Disease–Like Model Using Humanized GLP-1R MicePoster #: 1985-LBSession: Late Breaking Poster SessionDate: Sunday, June 22Time: 12:30 p.m. – 1:30 p.m. CT Summary: In a Parkinson's disease mouse model, oral administration of GSBR-5595, a small molecule GLP-1 receptor agonist distinct from Structure Therapeutics' clinical asset aleniglipron (GSBR-1290), significantly improved motor coordination and movement in both the rotarod and open field tests. Additionally, histopathological analyses revealed a significant increase in dopaminergic neurons. These findings suggest this GLP-1 receptor agonist showed neuroprotective effects by mitigating motor deficits and preserving dopaminergic neurons, highlighting a potential benefit in Parkinson's disease. About Structure TherapeuticsStructure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit Forward Looking StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the Company's future plans and prospects; the belief that ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner; the planned initiation of the ACCG-2671 Phase 1 study and the timing thereof; the belief that the oral small molecule approach gives Structure Therapeutics the opportunity to create more scalable, cost-effective treatments to meet the needs of patients with obesity and other related diseases, without compromising on efficacy or safety; the belief that Structure Therapeutics is well-positioned with one of the most robust oral small molecule metabolic franchises in the industry; and any expectations regarding the safety, efficacy or tolerability of ACCG-2671and other candidates under development. In addition, when or if used in this press release, the words and phrases 'anticipated,' 'expect,' 'on track,' 'plan,' 'potential,' 'to be,' and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to the results from earlier clinical studies not necessarily being predictive of future results, potential delays in the commencement, enrollment and completion of the Company's planned clinical studies, the Company's ability to advance ACCG-2671 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the Company's therapeutic candidates, competitive products or approaches limiting the commercial value of the Company's product candidates, the timing and results of preclinical and clinical studies, the Company's ability to fund development activities and achieve development goals, the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control, the impact of any global pandemics, inflation, tariffs, changes in monetary and fiscal policy, supply chain issues, rising interest rates, future bank failures and other macroeconomic factors on the Company's business, its ability to protect its intellectual property and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investors:Danielle KeatleyStructure Therapeutics Media:Dan Budwick1ABDan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation New preclinical data demonstrate that a single dose of INHBE siRNA leads to lower inflammation of adipose tissue with strong suppression of pro-inflammatory M1 macrophages in visceral fat in DIO mice, highlighting potential mechanistic insights into the risk reduction for type 2 diabetes (T2D) and coronary artery disease (CAD) suggested by human genetics CAMBRIDGE, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the presentation of preclinical data supporting WVE-007, its GalNAc-siRNA designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. The data demonstrate the ability of Wave's long-acting GalNAc-siRNA to reduce INHBE mRNA and Activin E protein, induce weight loss mainly through reduction of fat mass, and reduce pro-inflammatory macrophage recruitment in a diet-induced obese (DIO) mouse model. The data were highlighted today in an oral presentation at the American Diabetes Association's 85th Annual Scientific Sessions, taking place June 20 to 23, in Chicago. 'These exciting preclinical data highlighted in today's presentation both recapitulate human genetics findings and continue to support the potential of WVE-007 to drive weight reduction by reducing Activin E to induce lipolysis – or fat breakdown, preferentially reducing visceral fat, and decreasing inflammation of adipose tissue – all without impacting lean muscle mass. These data suggest a highly differentiated therapeutic profile with lower visceral fat, less insulin resistance and less inflammation, supporting potential for risk reduction of T2D, CAD and other obesity-related co-morbidities,' said Erik Ingelsson, MD, PhD, Chief Scientific Officer. 'Silencing of INHBE is an entirely orthogonal mechanism from GLP-1s, which are centrally acting and impact the digestive system and central nervous system to decrease appetite. If these preclinical data translate in the clinic, WVE-007 has the potential to transform the obesity treatment paradigm by delivering healthy weight loss, preservation of muscle mass, and infrequent dosing of once or twice a year. We are evaluating WVE-007 in our ongoing INLIGHT clinical trial in adults living with overweight or obesity, and we are on track to deliver the first clinical data in the second half of this year.' Human genetics provides strong evidence for INHBE as a therapeutic target. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier cardiometabolic profile, including less abdominal fat, lower triglycerides, and lower risk of type 2 diabetes and cardiovascular disease. These heterozygous carriers also exhibit favorable associations with liver traits, including reductions in cT1 (reflecting liver inflammation and fibrosis) and ALT (reflecting liver damage), with no impact on liver fat. The oral presentation titled, 'siRNA-INHBE Silencing in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile,' highlighted results from studies in DIO mice that evaluated monotherapy (INHBE-siRNA alone) as well as combination (INHBE siRNA and semaglutide), and maintenance (INHBE siRNA when semaglutide treatment is discontinued) treatment settings. Key results are as follows: A single dose of INHBE-siRNA led to robust target engagement, including reduction of INHBE mRNA and Activin E protein, a lipolysis suppressor that is upregulated in obesity. Liver INHBE mRNA was strongly correlated with serum Activin E levels following INHBE-siRNA treatment. A single dose of INHBE-siRNA led to weight loss on par with semaglutide. There was a decrease in diet-induced visceral adipose mass and shrinkage of adipocytes compared with PBS treatment, supporting the restoration of healthy adipose tissue with this mechanism of action. Muscle mass was preserved. Infiltration of activated macrophages in visceral adipose was significantly decreased by a single dose of INHBE-siRNA compared with PBS controls. INHBE-siRNA also significantly reduced proinflammatory M1 macrophage (CD11c positive) recruitment while sustaining levels of anti-inflammatory M2 macrophages in visceral fat, indicating an overall shift away from a pro-inflammatory state. When administered as an add-on to semaglutide, a single dose of INHBE-siRNA doubled the amount of weight loss, highlighting potential for combination treatment. Wave's INHBE siRNA curtailed rebound weight gain when semaglutide treatment was discontinued, highlighting its potential as an off-ramp and maintenance treatment following GLP-1 treatment. The full presentation can be accessed by visiting 'Scientific Presentations' on the Investors section of the Wave Life Sciences website: About Wave Life SciencesWave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and Obesity, as well as several preclinical programs utilizing the company's broad RNA therapeutics toolkit. Driven by the calling to 'Reimagine Possible', Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding our expectations for WVE-007 and the anticipated therapeutic benefits thereof; the anticipated timing of clinical data from our INLIGHT clinical trial of WVE-007; the novelty of our approach to silence INHBE mRNA in order to achieve healthy, sustainable weight loss and the potential for once- or twice-yearly dosing; the potential benefits of WVE-007 over existing obesity therapies; the potential of WVE-007's mechanism (INHBE) as a novel and unique obesity treatment to induce fat loss, preserve muscle, and drive weight loss; our understanding of our preclinical data for WVE-007 and our expectations of how such data will translate in humans; beliefs that Wave's portfolio of RNA medicines is differentiated, potentially best-in-class and potentially transformative; the broad potential of Wave's RNA medicines pipeline and oligonucleotide chemistry and any benefits that may arise as a result thereof. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled 'Risk Factors' in Wave's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. Contact:Kate RauschVP, Corporate Affairs and Investor Relations+1 617-949-4827Investors:InvestorRelations@ Media:MediaRelations@ in to access your portfolio
